BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition

被引：43
|
作者：
Andrews, Miles C. [1 ]
Behren, Andreas [2 ]
Chionh, Fiona [2 ]
Mariadason, John [2 ]
Vella, Laura J. [2 ]
Do, Hongdo [3 ]
Dobrovic, Alexander [3 ]
Tebbutt, Niall [1 ]
Cebon, Jonathan [1 ]
机构：
[1] Austin Hlth, Joint Ludwig Austin Oncol Unit, Melbourne, Vic, Australia
[2] Ludwig Inst Canc Res, Austin Branch, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 35期
关键词：
SQUAMOUS-CELL CARCINOMAS; ADVANCED MELANOMA; RAF INHIBITORS; MUTATIONS; SURVIVAL; V600E;
D O I：
10.1200/JCO.2013.50.4118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E448 / E451
页数：4
相关论文
共 50 条
  • [1] Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
    Chen, Wenjing
    Park, Jong-In
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [2] Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability
    Kim, Kyung-Ok
    Park, Woo-Jae
    Jung, YunJae
    Lee, Won-Suk
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (08) : 437 - 444
  • [3] PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma
    Deuker, Marian M.
    Durban, Victoria Marsh
    Phillips, Wayne A.
    McMahon, Martin
    CANCER DISCOVERY, 2015, 5 (02) : 143 - 153
  • [4] Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
    Zhou, XuSha
    Zhao, Jing
    Zhang, Jian V.
    Wu, Yinglin
    Wang, Lei
    Chen, Xiaoqing
    Ji, Dongmei
    Zhou, Grace Guoying
    VIRUSES-BASEL, 2021, 13 (09):
  • [5] MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells
    Miniotis, Maria Falck
    Arunan, Vaitha
    Eykyn, Thomas R.
    Marais, Richard
    Workman, Paul
    Leach, Martin O.
    Beloueche-Babari, Mounia
    CANCER RESEARCH, 2013, 73 (13) : 4039 - 4049
  • [6] MEK1/2 Inhibition as a Therapeutic Target in an NRAS-Mutated Pediatric Neuroendocrine Tumor
    Quinn, Colin H.
    Williams, Adele Plaisance
    Marayati, Raoud
    Markert, Hooper R.
    Aye, Jamie M.
    Stewart, Jerry Edward
    Yoon, Karina J.
    Beierle, Elizabeth A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : S206 - S207
  • [7] KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
    Yeh, Jen Jen
    Routh, Elizabeth D.
    Rubinas, Tara
    Peacock, Janie
    Martin, Timothy D.
    Shen, Xiang Jun
    Sandler, Robert S.
    Kim, Hong Jin
    Keku, Temitope O.
    Der, Channing J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) : 834 - 843
  • [8] Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers.
    Kinsey, Conan
    Camolotto, Soledad
    Boespflug, Amelie
    Gullien, Katrin
    Truong, Amanda
    Foth, Mona
    Shea, Jill
    Seipp, Michael
    Yap, Jeffrey
    Burrell, Lance
    Lum, David
    Whisenant, Jonathan
    Cavalier, Courtney
    Rehbein, Kaitren
    Cutler, Stephanie
    Afotler, Kajsa
    Welm, Alana
    Welm, Bryan
    Scaife, Courtney
    Snyder, Eric
    McMahon, Martin
    CANCER RESEARCH, 2020, 80 (19) : 23 - 23
  • [9] TAK-1 AND THIOREDOXIN METABOLISM INHIBITION: A POTENTIALLY POWERFUL COMBINATION THERAPY FOR KRAS-MUTATED COLON CANCERS
    Hrabe, J.
    Domann, F.
    Spitz, D.
    Mezhir, J.
    DISEASES OF THE COLON & RECTUM, 2014, 57 (05) : E298 - E298
  • [10] Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations
    Metzenmacher, Martin
    Goetz, Moritz
    Herold, Thomas
    Stuschke, Martin
    Aigner, Clemens
    Darwiche, Kaid
    Eberhardt, Wilfried E.
    Schuler, Martin
    Wiesweg, Marcel
    CLINICAL LUNG CANCER, 2021, 22 (05) : E668 - E672
12345